FDA Approves LEQEMBI IQLIK Subcutaneous Injection for Early Alzheimer's Initiation

The U.S. Food and Drug Administration (FDA) has approved a supplemental application for LEQEMBI IQLIK® (lecanemab-irmb), a once-weekly subcutaneous injection, as an initiation dose for the treatment of early Alzheimer's disease. This approval provides patients with a new option for starting treatment at home, reducing the frequency of clinic visits for infusions.

The approval of the subcutaneous LEQEMBI IQLIK injection is supported by clinical trial data demonstrating its efficacy and safety profile are comparable to intravenous administration. Studies indicated that the subcutaneous form achieved equivalent exposure and amyloid plaque removal, with similar expected rates of adverse events such as ARIA-E (edema) and ARIA-H (microhemorrhages) as the IV formulation.

This development offers increased treatment flexibility for patients and their caregivers. LEQEMBI IQLIK allows for initiation via subcutaneous injection, with the option to switch between subcutaneous and intravenous administration throughout the treatment course. This flexibility aims to lessen the burden of treatment delivery and potentially improve access to care.

Eisai and Biogen anticipate LEQEMBI IQLIK for initiation dosing to be available in the U.S. by late August 2026. The new dosing option is presented as a significant advancement in Alzheimer's care, enhancing convenience and supporting patient-centered treatment approaches.